Eima Zaidi, MD
Infectious Disease · Birmingham, ALNPI 1447237730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 65.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $272 and has fallen 55.7% since, to $120 in 2025. That places this record below the midpoint for infectious disease clinicians in AL, where the typical reported total is $923.
Across 45 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$491
- Insmed, Inc.$86
- Cumberland Pharmaceuticals, Inc.$43
- Merck$39
- La Jolla Pharmaceutical Company$32
- Amgen$29
- plus $34 from 2 others
What the payments were for
- Food & beverage$754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $491 |
| Insmed, Inc. | 3 | $86 |
| Cumberland Pharmaceuticals, Inc. | 3 | $43 |
| Merck | 2 | $39 |
| La Jolla Pharmaceutical Company | 1 | $32 |
| Amgen(2 entities) | 2 | $29 |
| Astellas Pharma US Inc | 1 | $18 |
| Gilead | 1 | $16 |
How this compares
$754 in reported general payments places this provider in the 45th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 72 | $26,391 |
| ErtapenemErtapenem Sodium | 36 | $15,948 |
| CeftriaxoneCeftriaxone Sodium | 57 | $8,080 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 34 | $6,855 |
| Cefazolin Sodium | 41 | $4,545 |
| Vancomycin Hcl | 25 | $2,993 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Birmingham
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Sonya HeathBirmingham$80K
- William GeislerBirmingham$63K
- Edward HookBirmingham$61K
- Edgar OvertonBirmingham$46K
- Jane SchwebkeBirmingham$42K
- Peter PappasBirmingham$25K
- Jeanne MarrazzoBirmingham$23K
- Todd McCartyBirmingham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.